IMVT — Immunovant, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1764013 ·
Last close
$39.71
Market Cap
$8.15B
52W High
$41.23
52W Low
$24.36
ADV30
1,628,198
Next earnings
2026-08-10
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 0 | — | -114,362,000 | -110,635,000 | 1,052,392,000 | 994,525,000 | 66,257,000 |
| Sep 2025 | 0 | — | -131,762,000 | -126,502,000 | 582,959,000 | 521,870,000 | 63,254,000 |
| Jun 2025 | 0 | — | -127,224,000 | -120,613,000 | 661,440,000 | 598,912,000 | 52,900,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-407,310,000
Investing CF
$-8,000
Financing CF
$595,756,000
CapEx
$-577,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.78
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,745,129,000
Inventory
—
Receivables
$3,946,000
ST Investments
—
EBIT TTM
$-532,902,000
Pretax Income TTM
$-505,391,000
Interest Exp TTM
—
Analysts
17
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -532,902,000 | -505,606,000 | 957,014,000 | 104,422,000 | — | -407,310,000 |
| Mar 2025 | 0 | -438,152,000 | -413,840,000 | 776,222,000 | 68,775,000 | — | -375,874,000 |
| Mar 2024 | 0 | -270,209,000 | -259,336,000 | 666,365,000 | 48,608,000 | — | -214,227,000 |
| Mar 2023 | 0 | -208,276,000 | -210,960,000 | 405,838,000 | 43,344,000 | — | -188,193,000 |
| Mar 2022 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-267,152,000
OpCashFlow TTM
$0
Assets (Latest)
$776,222,000
Forward EPS
$-2.44
Max Pain — expiry 2026-07-17
max pain strike: $28.00 · spot: $39.71 · call oi: 6,230 · put oi: 504
Expected Move to 2026-07-17:
±$3.75
(9.44%) —
implied range
$35.96 –
$43.46
· ATM straddle on $40.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGEN | REPLIGEN CORP | $8.14B | $144.24 | — |
| APGE | Apogee Therapeutics, Inc. | $8.25B | $133.65 | — |
| PCVX | Vaxcyte, Inc. | $8.41B | $58.21 | — |
| QGEN | QIAGEN N.V. | $8.56B | $41.51 | — |
| IBRX | ImmunityBio, Inc. | $8.61B | $8.22 | — |
News headlines (Yahoo Finance, 1h cache)
Immunovant (IMVT) Up 3.6% Since Last Earnings Report: Can It Continue?
2026-06-19 15:30 · Yahoo
Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight
2026-06-18 14:01 · Yahoo
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
2026-06-12 14:08 · Yahoo
Assessing Immunovant (IMVT) Valuation After Strong IMVT 1402 Phase 2 Rheumatoid Arthritis Trial Commentary
2026-06-05 08:12 · Yahoo
H.C. Wainwright Raises Price Target on Immunovant (IMVT) Following Positive Rheumatoid Arthritis Trial Data
2026-06-02 09:38 · Yahoo
Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating
2026-05-28 11:01 · Yahoo
This Biotech Is Up 60%. A Top Healthcare Fund Just Bought Another $11 Million
2026-05-24 14:39 · Yahoo
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
2026-05-24 14:33 · Yahoo
What to Know About This Fund's $6.6 Million UroGen Sale After a 600% Stock Surge
2026-05-23 22:40 · Yahoo
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
2026-05-23 22:33 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.